Long-term Effectiveness of Patient-Directed Education to Sustain Deprescribing: A Hybrid Implementation Trial

Abstract Deprescribing, stopping or dose-reducing medication, can avoid harms from potentially inappropriate medications (PIMs). We examined the effectiveness, sustainability, and safety of a patient-engagement strategy in a hybrid effectiveness-implementation pragmatic trial at three Veterans Affairs facilities. Subjects were mailed brochures for one of three PIMs (proton pump inhibitors, high-dose gabapentin, diabetes agents with hypoglycemia risk) if they had chronic active prescriptions before a primary care provider (PCP) visit. Control subjects received usual care. We determined PIM deprescribing (cessation or any dose reduction) 6- and 12-months after the visit, categorizing participants into four patterns. A multinomial mixed effect logistic regression with patients nested in PCPs, adjusting for intervention cohort, PIM, and site, tested the intervention effect on patterns. We assessed for possible adverse drug withdrawal events (ADWEs). Compared to controls (n = 2,448), intervention patients (n = 2,480) were significantly older (M = 70.8 vs. M = 70.0, p = 0.012) and less likely to be White (82% vs. 83%, p = 0.017). Intervention patients had more sustained deprescribing (6 and 12 months: 19.3% vs 15.1%), but comparable short-term (6 months only: 9.8% vs 10.5%) and delayed (12 months only: 13.9% vs 14.5%) deprescribing. In the adjusted regression, intervention patients were significantly more likely to exhibit sustained deprescribing (OR = 1.32 [95%CI=1.13, 1.55]) but not short-term (OR = 0.96 [95%CI=0.79, 1.16]) or delayed (OR = 0.99 [95%CI=0.84, 1.17]) deprescribing. There were five potential ADWEs (0.2% incidence rate); three assessed as not related and two as possibly related to the intervention. Despite the low intensity, patient-directed education materials are an effective implementation strategy to promote and sustain deprescribing with minimal ADWEs.

Authors

Institutions

Publication Details

Journal
Innovation in Aging
Published
2025-12-01
DOI
https://doi.org/10.1093/geroni/igaf122.1650
Primary Topic
Pharmaceutical Practices and Patient Outcomes
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Long-term Effectiveness of Patient-Directed Education to Sustain Deprescribing: A Hybrid Implementation Trial

Jacquelyn N. Pendergast, Kelly Stolzmann, Amy K. Rosen, Cameron Miller et al.
Innovation in Aging
Pharmaceutical Practices and Patient Outcomes
article

Long-term Effectiveness of Patient-Directed Education to Sustain Deprescribing: A Hybrid Implementation Trial

Jacquelyn N. Pendergast, Kelly Stolzmann, Amy K. Rosen, Cameron Miller, Amy M. Linsky, Karen Jones, Jolie B. Wormwood, Michael Still
article en

Abstract

Abstract Deprescribing, stopping or dose-reducing medication, can avoid harms from potentially inappropriate medications (PIMs). We examined the effectiveness, sustainability, and safety of a patient-engagement strategy in a hybrid effectiveness-implementation pragmatic trial at three Veterans Affairs facilities. Subjects were mailed brochures for one of three PIMs (proton pump inhibitors, high-dose gabapentin, diabetes agents with hypoglycemia risk) if they had chronic active prescriptions before a primary care provider (PCP) visit. Control subjects received usual care. We determined PIM deprescribing (cessation or any dose reduction) 6- and 12-months after the visit, categorizing participants into four patterns. A multinomial mixed effect logistic regression with patients nested in PCPs, adjusting for intervention cohort, PIM, and site, tested the intervention effect on patterns. We assessed for possible adverse drug withdrawal events (ADWEs). Compared to controls (n = 2,448), intervention patients (n = 2,480) were significantly older (M = 70.8 vs. M = 70.0, p = 0.012) and less likely to be White (82% vs. 83%, p = 0.017). Intervention patients had more sustained deprescribing (6 and 12 months: 19.3% vs 15.1%), but comparable short-term (6 months only: 9.8% vs 10.5%) and delayed (12 months only: 13.9% vs 14.5%) deprescribing. In the adjusted regression, intervention patients were significantly more likely to exhibit sustained deprescribing (OR = 1.32 [95%CI=1.13, 1.55]) but not short-term (OR = 0.96 [95%CI=0.79, 1.16]) or delayed (OR = 0.99 [95%CI=0.84, 1.17]) deprescribing. There were five potential ADWEs (0.2% incidence rate); three assessed as not related and two as possibly related to the intervention. Despite the low intensity, patient-directed education materials are an effective implementation strategy to promote and sustain deprescribing with minimal ADWEs.

Innovation in AgingVol. 9(Supplement_2)
University of New Hampshire (US), VA Boston Healthcare System (US)
Openalex Percentile: Top 32%
Pharmaceutical Practices and Patient Outcomes
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.